SCHEMBL23148104

SCHEMBL23148104

COc1cncc2[nH]c(C(=O)O)cc12

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.53
▸ HPGD P15428 2/20 0.53
▸ IDO1 P14902 8/20 0.44
▸ ALDH1A1 P00352 2/20 0.43
▸ LMNA P02545 2/20 0.43
▸ TDO2 P48775 5/20 0.43
▸ SRD5A2 P31213 2/20 0.42
▸ FLT3 P36888 1/20 0.42
▸ NPC1 O15118 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ SRD5A1 P18405 1/20 0.41
▸ RHEB Q15382 1/20 0.41
▸ GRIN1 Q05586 1/20 0.41
▸ EIF4A3 P38919 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ RCE1 Q9Y256 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29721999 0.86 IDO1 (0.43) KDM4EHPGDIDO1FLT3NPC1
SCHEMBL23148095 0.84 ULK1 (0.48) KDM4EHPGDIDO1ALDH1A1LMNA
SCHEMBL23147890 0.77 EIF4A3 (0.51) KDM4EHPGDIDO1ALDH1A1LMNA
SCHEMBL1144683 0.76 IDO1 (0.55) KDM4EHPGDIDO1ALDH1A1LMNA
SCHEMBL6704955 0.76 KDM4E (0.54) KDM4EHPGDIDO1ALDH1A1LMNA
SCHEMBL913914 0.76 FLT3 (0.68) KDM4EHPGDIDO1ALDH1A1LMNA
SCHEMBL29414307 0.76 FLT3 (0.68) KDM4EHPGDIDO1ALDH1A1LMNA
SCHEMBL26177978 0.76 KDM4E (0.54) KDM4EHPGDIDO1ALDH1A1LMNA
SCHEMBL23147490 0.76 GRIN1 (0.65) KDM4EHPGDLMNARHEBGRIN1
SCHEMBL29202505 0.76 GRIN1 (0.44) KDM4EHPGDALDH1A1LMNASRD5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002372-A1 AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) 2023-01-05 — — US disclosed
US-20230002372-A1 AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) 2023-01-05 — — US disclosed
EP-4034108-A1 AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS The Global Alliance for TB Drug Development, Inc. (US) 2022-08-03 — — EP disclosed
CN-114746090-A Azaindole carboxamide compounds for the treatment of mycobacterial infections 结核病药物开发全球联盟公司 2022-07-12 — — CN disclosed
WO-2021062316-A1 AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) 2021-04-01 — — WO disclosed
WO-2021062316-A1 AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) 2021-04-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002372-A1 AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS AZI2, AADAC, TPMT KDM4E 1203/4885HPGD 1569/4885IDO1 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback